Integrated analysis of cell-free DNA for the early detection of cancer in people with Li-Fraumeni Syndrome

Derek Wong, Ping Luo, Leslie E. Oldfield, Haifan Gong, Ledia Brunga, Ron Rabinowicz, Vallijah Subasri, Clarissa Chan, Tiana Downs, Kirsten M. Farncombe, Beatrice Luu, Maia Norman, Jenna Eagles, Stephenie Pederson, Johanna Wellum, Arnavaz Danesh, Stephenie D. Prokopec, Eric Y. Stutheit-Zhao, Nadia Znassi, Bernard Lam, Kayla Marsh, Yogi Sundaravadanam, Dax Torti, David Malkin, Raymond H. Kim, Trevor J. PughmedRxiv 2022 · DOI

Introduction

Li-Fraumeni Syndrome (LFS) represents one of the most challenging clinical scenarios in oncology. Caused by germline pathogenic variants in the TP53 tumor suppressor gene, LFS confers a near 100% lifetime risk of developing a broad spectrum of malignancies, often occurring in childhood or early adulthood. Current management relies on intensive surveillance protocols—such as the "Toronto Protocol"—which involve frequent whole-body MRIs, brain MRIs, and physical examinations. While these protocols significantly improve survival through early detection, they are physically taxing, emotionally draining, and economically burdensome, leading to significant non-compliance rates.

Liquid biopsy, the analysis of cell-free DNA (cfDNA) fragments in the blood, offers a minimally invasive alternative. However, detecting cancer at its earliest stages is difficult due to the extremely low concentration of tumor-derived DNA (ctDNA) in the circulation. This study presents a framework for a multi-modal liquid biopsy assay designed to overcome these sensitivity limits by integrating genomic, fragmentomic, and epigenetic signals.

Methodology: A Multi-Modal Framework

Rather than relying on a single biomarker, the researchers developed an integrated analysis of four distinct cfDNA features to provide a holistic view of the cellular milieu:

  1. Targeted Sequencing (TS): Deep sequencing (~20,000X) of an 829-probe panel to identify somatic mutations in TP53 and other cancer-associated genes.
  2. Copy Number Alterations (CNA): Shallow Whole Genome Sequencing (sWGS) and the ichorCNA tool to detect large-scale chromosomal gains and losses, a hallmark of many LFS-associated tumors.
  3. Fragmentomics: Analysis of cfDNA size distribution. Because tumor cells tend to shed shorter DNA fragments than healthy cells, fragment length serves as a proxy for tumor presence.
  4. Methylation (cfMeDIP-seq): Cell-free methylated DNA immunoprecipitation sequencing to identify epigenetic fingerprints. This allows for the detection of cancer-specific signals even when no mutations are present and can help identify the "tissue of origin."

These modalities were combined using a logistic regression model to generate a unified "cancer-positive" or "cancer-negative" classification.

Study Results and Clinical Insights

The study analyzed 196 blood samples from 89 LFS patients (including 26 pediatric and 63 adult participants) and 29 healthy controls to establish a baseline.

Enhanced Sensitivity through Integration

The primary finding was the synergistic effect of multi-modal integration. While individual methods like mutation calling caught only approximately 40% of active cancers, the integrated model achieved a sensitivity of 79.4% in samples from patients with active cancer. This represents a 37.5% to 58.8% improvement over any single-modality approach used in isolation.

Molecular Lead Time

One of the most significant clinical implications is the "molecular lead time." The assay detected cancer-associated signals in 17.6% of samples that were considered clinically negative at the time of collection. In these cases, the liquid biopsy flagged the presence of cancer up to 16 months before it was detectable by conventional imaging or clinical symptoms. This suggests that liquid biopsy could serve as an "early warning system," prompting more frequent or targeted imaging for high-risk individuals.

The LFS "Baseline" Shift

The researchers observed that LFS patients—even those without active cancer—exhibit shorter cfDNA fragments compared to healthy non-carriers. This suggests that the germline TP53 mutation may fundamentally alter the landscape of cell death and DNA release across the entire body, creating a unique biological "noise" that must be accounted for in LFS-specific diagnostics.

Clinical Utility and Future Directions

The assay demonstrated a Negative Predictive Value (NPV) of 97.6% in the cancer-negative LFS group. In a clinical setting, a high NPV is invaluable; it provides clinicians and patients with a high degree of confidence when a test returns a negative result, potentially allowing for the spacing out of more invasive or burdensome imaging procedures.

Limitations and Challenges

Despite the success of the framework, several hurdles remain for clinical implementation:

  • Biological Noise: The altered cfDNA baseline in LFS patients suggests that future work should focus on patient-specific longitudinal baselines, comparing a patient's current results against their own historical "healthy" samples.
  • Scalability: The requirement for three different sequencing workflows (TS, sWGS, and cfMeDIP-seq) increases the cost and computational requirements, which may limit immediate adoption in standard clinical labs.
  • Cohort Size: While large for a rare syndrome, larger cohorts will be needed to further refine the machine learning models used for multi-modal integration.

Conclusion

This study provides a robust proof-of-concept for the use of multi-modal liquid biopsy in high-risk populations. By integrating genomic and epigenetic signals, the framework significantly improves the sensitivity of early cancer detection in Li-Fraumeni Syndrome, offering a potential path toward less burdensome and more proactive clinical surveillance.

Summary updated

Abstract

Summary Despite advances in cancer therapeutics, early detection is often the best prognostic indicator for survival ( 1 ). People with Li-Fraumeni syndrome harbor a germline pathogenic variant in the tumor suppressor gene TP53 ( 2 ) and face a near 100% lifetime risk of developing a wide spectrum of, often multiple, cancers ( 3 ). TP53 mutation carriers routinely undergo intensive surveillance protocols which, although associated with significantly improved survival, are burdensome to both the patient and the health care system ( 4 ). Liquid biopsy, the analysis of cell-free DNA fragments in bodily fluids, has become an attractive tool for a range of clinical applications, including early cancer detection, because of its ability to provide real-time holistic insight into the cellular milieu ( 5 ). Here, we assess the efficacy of a multi-modal liquid biopsy assay that integrates a targeted gene panel, shallow whole genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a cohort of Li-Fraumeni syndrome patients: 196 blood samples from 89 patients, of which 26 were pediatric and 63 were adults. Our integrated analysis was able to detect a cancer-associated signal in 79.4% of samples from patients with active cancer, a 37.5% – 58.8% improvement over each individual analysis. Through analysis of patient plasma at cancer negative timepoints, we were able to detect cancer-associated signals up to 16 months prior to occurrence of cancer as detected by conventional clinical modalities in 17.6% of TP53 mutation carriers. This study provides a framework for the integration of liquid biopsy into current surveillance methods for patients with Li-Fraumeni syndrome.
BibTeX
@misc{wong2022integrated,
  author = {Derek Wong and Ping Luo and Leslie E. Oldfield and Haifan Gong and Ledia Brunga and Ron Rabinowicz and Vallijah Subasri and Clarissa Chan and Tiana Downs and Kirsten M. Farncombe and Beatrice Luu and Maia Norman and Jenna Eagles and Stephenie Pederson and Johanna Wellum and Arnavaz Danesh and Stephenie D. Prokopec and Eric Y. Stutheit-Zhao and Nadia Znassi and Bernard Lam and Kayla Marsh and Yogi Sundaravadanam and Dax Torti and David Malkin and Raymond H. Kim and Trevor J. Pugh},
  title = {{Integrated analysis of cell-free DNA for the early detection of cancer in people with Li-Fraumeni Syndrome}},
  year = {2022},
  doi = {10.1101/2022.10.07.22280848},
  howpublished = {medRxiv},
}
Figure